Document:

EXHIBIT
      10.24

     

    AMENDED
      AND RESTATED

    TECHNOLOGY
      LICENSE AGREEMENT

     

    This
      AMENDED
      AND RESTATED TECHNOLOGY LICENSE AGREEMENT (the
      “Agreement”)
      is
      made and entered into on January 12, 2006 by and among OSMOTEX
      AS,
      a
      Norwegian corporation (“Licensor”),
      OSMOTEX
      USA, INC., a
      Florida
      corporation (“Licensee”)
      and
IQ
      MICRO INC. (formerly
      IQ Medical Corp.),
      a
      Colorado corporation (“Sublicensee”).
      

     

    RECITALS

     

    WHEREAS,
      Licensor and Licensee entered into that certain Technology License Agreement
      dated June 2005 (the “Original
      Agreement”)
      and
      now desire to amend and restate the terms and conditions of their license
      arrangement; and

     

    WHEREAS,
      Licensor and Licensee now desire to amend and restate the terms and conditions
      of their license arrangement to include a sublicense provision and terms and
      conditions thereof; and

     

    WHEREAS,
      Licensor owns all of the rights, title and interest in and to certain technology
      and intellectual property (the “Technology”)
      as
      described on Exhibit
      A hereto;
      and

     

    WHEREAS,
      subject
      to and in accordance with the terms and conditions of this Agreement, Licensor
      desires to grant to Licensee, and Licensee desires to obtain from Licensor,
      the
      right and license to utilize the Technology as specifically provided in this
      Agreement; and

     

    WHEREAS,
      subject
      to and in accordance with the terms and conditions of this Agreement, Licensee
      desires to grant to Sublicensee, and Sublicensee desires to obtain from
      Licensee, the right and sublicense to utilize the Technology as specifically
      provided in this Agreement.

     

    NOW,
      THEREFORE, in
      consideration of the foregoing recitals and the covenants, representations,
      warranties and agreements set forth in this Agreement, and other good and
      valuable consideration, the receipt and sufficiency of which are hereby
      acknowledged, Licensor, Licensee and Sublicensee, intending to be legally bound,
      hereby agree as follows:

     

    1.  TERM
      OF AGREEMENT.
      This
      Agreement shall commence upon the date first written above and shall continue
      in
      full force and effect
      indefinitely until terminated pursuant to the provisions of this
      Agreement
      (the
“Term”).

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

     

    2.  GRANT
      OF LICENSE.

     

    2.1  Recitals.
      The
      recitals set forth above are hereby incorporated herein by reference. The
      Original Agreement is hereby superseded, in its entirety, by this
      Agreement.

     

    2.2  Grant
      of License to Licensee.
      Licensor hereby grants to Licensee an exclusive, irrevocable, royalty-free,
      fully paid-up, non-transferable, indivisible, perpetual right and license,
      throughout the world, subject to the terms of this Agreement, to (a) use,
      market, research, develop, modify, sell and have sold the Technology, (b) use,
      copy, execute, reproduce, translate, modify, improve, adapt, enhance, display,
      perform, and otherwise commercially exploit, in any medium or distribution
      technology whatsoever, whether known or unknown, the Technology and the
      Intellectual Property Rights (as defined below), in connection with Technology,
      in furtherance of the foregoing rights, and (c) sublicense any and all of the
      rights herein granted to IQ Micro Inc. (formerly IQ Medical Corp.), located
      at
      500 Australian Avenue, Suite 700, West Palm Beach, Florida, 33401.

     

    2.3  Grant
      of Sublicense to Sublicensee.
      Licensee hereby grants to Sublicensee an exclusive, irrevocable, royalty-free,
      fully paid-up, non-transferable, indivisible, perpetual right and license,
      throughout the world, subject to the terms of this Agreement, to (a) use,
      market, research, develop, modify, sell and have sold the Technology, (b) use,
      copy, execute, reproduce, translate, modify, improve, adapt, enhance, display,
      perform, and otherwise commercially exploit, in any medium or distribution
      technology whatsoever, whether known or unknown, the Technology and the
      Intellectual Property Rights (as defined herein), in connection with Technology,
      in furtherance of the foregoing rights, and (c) sub-sublicense the Technology
      to
      any other party or parties in its sole discretion. The Sublicensee shall not
      be
      required to notify or obtain the consent of the Licensee or the Licensor in
      connection with any such sub-sublicense by the Sublicensee.

     

    2.4  Ownership.
      Licensor owns and shall at all times continue to own all rights, title and
      interest in and to the Technology, including, without limitation, all
      Intellectual Property Rights related to the Technology, and nothing contained
      in
      or arising out of this Agreement shall in any way limit or reduce Licensor’s
      ownership rights in the Technology or the Intellectual Property Rights.
      Derivative works related to or arising from the Technology resulting from
      Sublicensee’s independent research and development or at Sublicensee’s expense
      (the “Derivative
      Works”)
      shall
      be owned by the Sublicensee. 

     

    2.5  Intellectual
      Property Rights.
      “Intellectual
      Property Rights”
means
      any and all now known or hereafter known or discovered tangible and intangible:
      (i) rights associated with works of authorship throughout the universe,
      including, but not limited to, copyrights, moral rights and mask-works; (ii)
      trademark and trade name rights and similar rights; (iii) trade secret rights;
      (iv) patents, designs, algorithms and other industrial property rights; (v)
      all
      other intellectual and industrial property rights of every kind and nature
      throughout the universe, however named or designated, including, without
      limitation, all characters, artwork, graphics, audio-visual components,
      recordings, films, photographs and or materials related to the Technology;
      and
      (vi) all registrations, initial applications, renewals, extensions,
      continuations, divisions or reissues of the above, whether now or hereafter
      in
      force.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    Patent
      Filing and Maintenance and Intellectual Property Rights
      Development.
      Licensor shall be responsible at its own expense for the preparation, filing,
      prosecution maintenance and renewal of all patent applications and patents
      within the Technology and arising out of, related to or in connection with
      any
      new patent development and applications, including, but not limited to,
      microfluidics technology patents and Patent Cooperation Treaty application
      PCT/NO 03/00246 "Microfluidic
      Actuator,"
      Priority
      date: 030715 and Patent Cooperation Treaty application PCT/NO 03/00247
"Fabric
      Material With Improved Liquid Transport,"
      Priority
      date: 030715. Licensor shall, in a timely manner, keep the Licensee and
      Sublicensee informed in writing of the progress of all patent applications
      within the Technology and arising out of, related to or in connection with
      any
      new patent development and applications, including but not limited to,
      microfluidics technology patents and Patent Cooperation Treaty application
      PCT/NO 03/00246 "Microfluidic
      Actuator,"
      Priority
      date: 030715 and Patent Cooperation Treaty application PCT/NO 03/00247
"Fabric
      Material With Improved Liquid Transport,"
      Priority
      date: 030715, and shall give the Licensee and Sublicensee reasonable opportunity
      to comment on the type and scope of useful claims, patent filings, and
      prosecution strategy. Licensor shall promptly so verify in writing to Licensee
      and Sublicensee all renewals, maintenance and payment of all such costs.
      Licensor shall promptly notify Licensee and Sublicensee of any new intellectual
      property that is created after the date of this Agreement, including, but not
      limited to new Intellectual Property Rights.

     

    2.6  Public
      Disclosure.
      Licensor shall at all times during and after the Term have complete control
      over
      any materials or documents (including, without limitation, advertising and
      publicity materials) that in any way refer to the Technology or the Intellectual
      Property Rights, and Licensee and Sublicensee shall present all such materials
      and documents to Licensor for approval (which shall not be unreasonably
      withheld) within a reasonable period of time prior to Licensee’s and
      Sublicensee’s proposed use or dissemination of such materials or
      documents.

     

    2.7  Section
      365(n) of The Bankruptcy Code.
      All
      rights and licenses granted under or pursuant to this Agreement by Licensor
      to
      Licensee (including the license) and all rights granted under or pursuant to
      this Agreement by Licensee to Sublicensee (including the sublicense) are, and
      shall otherwise be deemed to be, for the purposes of Section 365(n) of the
      United States Bankruptcy Code (the “Bankruptcy
      Code”),
      licenses to rights in “intellectual property” as defined under the Bankruptcy
      Code. As licensee of such rights under this Agreement, Licensee shall retain
      and
      may fully exercise all of its rights and elections under the Bankruptcy Code.
      As
      sublicensee of such rights under this Agreement, Sublicensee shall retain and
      may fully exercise all of its rights and elections under the Bankruptcy Code.
      Upon the event of the commencement of bankruptcy proceedings by or against
      Licensor under the Bankruptcy Code, Licensee shall be entitled to retain all
      of
      its rights under this Agreement or any agreement supplementary to this Agreement
      (including the license). Upon the event of the commencement of bankruptcy
      proceedings by or against Licensee under the Bankruptcy Code, Licensee shall
      be
      deemed as licensor for the purposes of Section 365(n) of the Bankruptcy Code
      thereby permitting sublicensee to retain and fully exercise all of the
      protections and rights of Section 365(n) of the Bankruptcy Code and Sublicensee
      shall be entitled to retain all of its rights under this Agreement or any
      agreement supplementary to this Agreement (including the sublicense).

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    2.8  Delivery
      of Technology.
      Upon
      execution of this Agreement, Licensor shall deliver to Licensee all necessary
      materials and information constituting the Technology and Licensee shall deliver
      to Sublicensee all necessary materials and information constituting the
      Technology. 

     

    3.  INDEMNIFICATION.
      Licensor and Licensee will, at their respective expense, defend, indemnify
      and
      hold each other and Sublicensee and all of the other’s and Sublicensee’s
      respective shareholders, directors, officers, members, employees, affiliates,
      consultants, independent contractors and agents harmless from any and all loss,
      demand, damages, suit, judgment, claim, liability, costs or expenses incurred
      of
      any kind whatsoever, including attorneys’ fees and expenses or cause of action
      brought against the other or Sublicensee that results, directly or indirectly,
      from or arise out of or related to or is attributable to Licensor’s, Licensee’s
      or Sublicensee’s use of the Technology or the Intellectual Property Rights such
      as patent, trade secret, trademark and copyright infringement; and provided
      further, that Licensor and Licensee shall indemnify and hold harmless
      Sublicensee and its respective shareholders, directors, officers, members,
      employees, affiliates, consultants, independent contractors and agents harmless
      from any and all loss, demand, damages, suit, judgment, claim, liability, costs
      or expenses incurred of any kind whatsoever, including attorneys’ fees and
      expenses or cause of action brought against the other or Sublicensee that
      results, directly or indirectly, from or arise out of or related to or is
      attributable to Sublicensee’s sub-sublicense of the Technology. Licensee or
      Licensor shall indemnify, defend, and hold harmless the other and Sublicensee
      and their respective successors, shareholders, directors, officers, members,
      employees, affiliates, consultants, independent contractors and agents, from
      and
      against any and all loss, demand, damages, suit, judgment, claim, liability,
      costs or expenses incurred of any kind whatsoever, including attorneys’ fees and
      expenses or cause of action brought against the other or Sublicensee that
      results, directly or indirectly, from or arise out of or related to or is
      attributable to: (i) fraud, negligence, recklessness, willful misconduct or
      omission of the Licensee or Licensor, its employees, affiliates, agents,
      consultants, subcontractors or independent contractors; (ii) infringement or
      misappropriation of any intellectual property right of any third party; (iii)
      product liability, death or bodily injury and property damage (real and
      personal) in connection with this Agreement and the Technology, Intellectual
      Property Rights and sub-sublicenses; and (iv) Licensee’s, Licensor’s or
      Sublicensee’s breach of any obligations in this Agreement, including breach of
      the confidentiality provisions of this Agreement.

     

    3.1  Notice.
      A party
      seeking indemnification pursuant to this Section 3 (an “Indemnified
      Party”)
      from
      or against the assertion of any claim by a third person (a “Third
      Person Assertion”)
      shall
      give prompt written notice to the party from whom indemnification is sought
      (the
“Indemnifying
      Party”);
      provided however, that failure to give prompt notice shall not relieve the
      Indemnifying Party of any liability hereunder (except to the extent the
      Indemnifying Party has suffered actual material prejudice by such
      failure).

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    3.2  Assumption
      of Defense.
      Within
      ten business days of receipt of notice from the Indemnified Party pursuant
      to
      Section 3.3 hereof, the Indemnifying Party shall have the right exercisable
      by
      written notice to the Indemnified Party, to assume the defense of a Third Person
      Assertion. If the Indemnifying Party assumes such defense, the Indemnifying
      Party may select counsel, which shall be reasonably acceptable to the
      Indemnified Party.

     

    3.3  Failure
      to Defend.
      If the
      Indemnifying Party (a) does not assume the defense of any Third Person Assertion
      in accordance with Section 3.4 hereof; or (b) having so assumed such defense,
      unreasonably fails to defend against such Third Person Assertion, then upon
      ten
      days written notice to the Indemnifying Party, the Indemnified Party may assume
      the defense of such Third Person Assertion. In such event, the Indemnified
      Party
      shall be entitled under this Section 3 as part of its damages to indemnification
      for the costs of such defense.

     

    3.4  Conflicts
      of Interest.
      If the
      Indemnifying Party has been advised by the written opinion of counsel to the
      Indemnified Party that the use of the same counsel to represent both the
      Indemnified Party and the Indemnifying Party would present a conflict of
      interest, then the Indemnified Party may select its own counsel to represent
      the
      Indemnified Party in the defense of the matter and the costs of such defense
      shall be borne by the Indemnifying Party. The Indemnifying Party shall be
      entitled to continue to handle its own representation in such matter through
      its
      own counsel.

     

    3.5  Settlement.
      The
      party controlling the defense of a Third Person Assertion shall have the right
      to consent to the entry of judgment with respect to, or otherwise settle, such
      Third Person Assertion with the prior written consent of the other party, which
      consent shall not be unreasonable withheld.

     

    3.6  Participation.
      The
      Indemnifying Party and the Indemnified Party shall cooperate, in the defense
      or
      prosecution of any Third Person Assertion. The Indemnified Party shall have
      the
      right to participate, at its own expense, in the defense or settlement of any
      Third Person Assertion. 

     

    3.7  Unauthorized
      Modifications.
      The
      indemnification obligation of this Section 3 shall not apply to any claim
      arising out of the Licensee’s or Sublicensee’s modification of the Technology
      not authorized by the Licensor, to the extent that alleged infringement would
      have been avoided absent such modification.

     

    4.  LICENSE
      FEES.
      

     

    4.1  License
      Fee.
      In
      consideration for the foregoing license and the rights granted to Licensee
      hereunder, Licensee issued to Licensor one hundred shares of Licensee’s $0.001
      par value per share common stock. 

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    4.2  Sublicense
      Fee.
      In
      consideration for the foregoing sublicense and the rights granted to Sublicensee
      hereunder, (1) Sublicensee acknowledges that it issued, and Licensor and
      Licensee acknowledge the Licensee’s receipt of, 42,670,000 shares of
      Sublicensee’s $0.0001 par value per share common stock and (2) Sublicensee made
      payment of a license fee in the amount of $300,000 (the “License
      Fee”)
      of
      which Licensee and Licensor hereby acknowledge receipt and further acknowledge
      that Sublicensee did pay the License Fee in full.

     

    5.  TAXES.
      Licensor, Licensee and Sublicensee shall cooperate to more accurately determine
      and minimize their respective tax liability. Each party will provide tax
      information or tax documents reasonably requested by another party. Each party
      will promptly notify the other parties of any claim for taxes asserted with
      respect to this Agreement by a taxing authority with jurisdiction over either
      party. With respect to any claim arising out of a tax form or return signed
      by a
      party to this Agreement, the signing party may control the response to and
      settlement of the claim, but the other parties may participate to the extent
      each may be liable.

     

    6.  PROPRIETARY
      INFORMATION.
      Licensee and Sublicensee acknowledge that, with the exception of the Derivative
      Works, Licensor is the owner of the Intellectual Property Rights embodied in
      or
      otherwise related to the design and development of the Technology. Licensee
      and
      Sublicensee covenant acknowledge and agree that, with the exception of the
      Derivative Works, by entering into this Agreement, Licensee and Sublicensee
      do
      not acquire any right, title, or interest in or to the Technology or the
      Intellectual Property Rights or any technologies used in the same except as
      granted by this Agreement. Licensee and Sublicensee covenant and agree that
      they
      shall not make any use of the Intellectual Property Rights or Technology except
      as expressly permitted by this Agreement. Licensee and Sublicensee shall
      promptly notify Licensor of any actual, threatened or suspected infringement
      of
      the any Intellectual Property Rights of Licensor that is known or should
      reasonably be known by Licensee or Sublicensee.

     

    7.  INFRINGEMENT
      OF THE LICENSED PATENTS BY THIRD PARTIES.

     

    7.1  Notice.
      Each
      party shall notify the other parties within thirty days of obtaining knowledge
      of a possible infringement of the Technology or Intellectual Property
      Rights.

     

    7.2  Licensor
      Sole Right.
      Licensor shall have the sole right, but not the obligation, at its own expense,
      to take all steps that, in Licensor’s sole discretion, are necessary or
      appropriate to protect and to enforce any of the Technology and Intellectual
      Property Rights including the initiation of legal proceedings against any third
      party who has infringed or ever infringes any Technology and Intellectual
      Property Rights. Any damage, cost, award fee, recovery, or compensation paid
      by
      any third party in connection with any proceeding initiated or carried on at
      Licensor expense (whether by way of settlement or otherwise) shall be retained
      by Licensor. Licensor shall not enter into any settlement, consent judgment,
      or
      any other voluntary final disposition of any infringement action under this
      section without the prior written consent of Licensee and
      Sublicensee.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    7.3  Licensee
      and Sublicensee Right.
      In the
      event that Licensor elects not to initiate legal proceedings under Section
      7.2,
      Licensor shall provide prompt written notice of such to Licensee and Sublicensee
      and (1) Licensee shall have the right, but not the obligation, to initiate
      legal
      proceedings against the infringer at Licensee’s sole expense, naming Licensor as
      a party, if so required by law. In the event that Licensee elects not to
      initiate such legal proceedings, Licensee shall provide prompt written notice
      of
      such to Sublicensee and Licensor and (2) Sublicensee shall have the right,
      but
      not the obligation, to initiate legal proceedings against the infringer at
      Sublicensee’s sole expense, naming Licensor and Licensee as parties, if so
      required by law. Licensor and Licensee agree to become a named party of such
      legal proceedings if so requested by Licensee or Sublicensee, as applicable
      and
      appropriate. Any damage, cost, award fee, recovery, or compensation paid by
      any
      third party in connection with any proceeding initiated or carried on at
      Licensee’s or Sublicensee’s expense pursuant to this section (whether by way of
      settlement or otherwise) shall be retained by Licensee or Sublicensee, as
      applicable (i.e. whomever initiated the proceeding). Licensee and Sublicensee
      shall notify Licensor promptly in writing of any settlement, consent judgment,
      or any other voluntary final disposition of any infringement action under this
      section.

     

    7.4  In
      the
      event that any party (“Initiating
      Party”)
      desires to initiate, initiates, or carries on any legal proceeding to enforce
      or
      to protect any of the Technology or Intellectual Property Rights under Sections
      7.2 and 7.3, the other party (the “Non-initiating
      Party”)
      hereto
      shall fully co-operate with and will supply all assistance reasonably requested
      by the initiating party. The Initiating Party shall have sole control of the
      proceeding and shall bear reasonable expenses (excluding legal fees) incurred
      by
      the Non-initiating Party in providing such assistance and cooperation as the
      Initiating Party may request. The Non-initiating Party shall be entitled to
      participate in any proceedings initiated or carried on by the Initiating Party
      with counsel selected by it, but at its own expense.

     

    8.  TERMINATION.

     

    8.1  Termination.
      Sublicensee shall have the right to terminate this Agreement with thirty days
      prior written notice to Licensor and Licensee. This Agreement and the rights
      and
      benefits granted to the Sublicensee in this Agreement and the rights and
      benefits granted to Sublicensee by Licensor and Licensee arising out of, related
      to, directly or indirectly, and in connection with this Agreement shall not
      terminate or alter or be terminated or altered in the event that Licensee
      becomes insolvent, dissolves, merges, enters into a business combination,
      becomes bankrupt or otherwise ceases to exist, unless Sublicensee gives written
      notice to Licensor or Licensee of such termination.

     

    8.2  No
      Liability Upon Termination.
      Except
      as specifically provided herein, none of the parties hereto shall be liable
      by
      reason of termination of the Term to the other parties hereto for compensation,
      reimbursement or damages on account of the loss of prospective profits on
      anticipated sales or on account of expenditures, investments, or leases of
      Licensor, Licensee, Sublicensee or otherwise. Each party covenants and agrees
      that it shall not file suit or bring an action seeking to impose such liability
      or recover damages for any such claims.

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    9.  TERMINATION
      EVENTS.
      Licensor, Licensee and Sublicensee covenant and agree that upon the event of
      Licensee’s dissolution, winding up, business combination (such as an
      acquisition, merger, consolidation, reorganization, joint venture, sale or
      purchase of all or a portion of its business or the business of another party)
      or the commencement of bankruptcy proceedings by or against Licensee under
      the
      Bankruptcy Code (collectively, the “Termination
      Events”),
      all
      parties hereto shall immediately take any and all actions necessary to terminate
      the Agreement and any and all amendments thereto, and Licensor shall,
      simultaneously with the occurrence of a Termination Event, enter into a new
      Technology License Agreement by and between Licensor and Sublicensee
      (“New
      Agreement”)
      dated
      the same date as such Termination Event, provided that in the New Agreement:
      (1)
      IQ Micro Inc. as Sublicensee and text related thereto is deleted entirely,
      (2)
      Osmotex USA, Inc., as a party, as Licensee and text related thereto, is deleted
      entirely, and (3) IQ Micro Inc. is defined as “Licensee” and as such becomes
      Licensor’s direct licensee of the Technology and the Intellectual Property
      Rights (replacing Osmotex USA, Inc. as Licensee). Notwithstanding the foregoing,
      the New Agreement shall be identical to the Agreement and all amendments
      thereto. The New Agreement shall also contain any deletions or additions that
      are reasonably required to effect the intent of this Section 9.

     

    10.  REPRESENTATIONS
      AND WARRANTIES.

     

    10.1  Licensor
      and Licensee each individually hereby represent and warrant that it is not
      subject to any obligation that would prevent it from entering into this
      Agreement and Licensor’s offer to provide the Technology and Intellectual
      Property Rights to the Licensee and Licensee’s acceptance of such offer has in
      no way caused or induced Licensor to breach any contractual obligation to any
      party; and further, Licensee’s offer to provide the Technology and Intellectual
      Property Rights to the Sublicensee and Sublicensee’s acceptance of such offer
      has in no way caused or induced Licensee to breach any contractual obligation
      to
      any party.

     

    10.2  Licensor
      and Licensee each individually represent and warrant that there is no and at
      no
      time has there been any action, suit, claim investigation or proceeding pending,
      or, to the best of its knowledge, threatened against, by or affecting it which
      might affect: (a) its ability to enter into this Agreement; (b) its performance
      of its obligations herein; or (c) Licensee’s and Sublicensee’s use of the
      Technology or Intellectual Property Rights. Licensor and Licensee each
      individually further represent and warrant that it does not know of any basis
      for any such action. Licensor and Licensee shall promptly notify each other
      and
      Sublicensee if any of the foregoing types of litigation arises during the term
      of this Agreement that might affect (i) Licensor’s or Licensee’s performance of
      their respective obligations herein or (ii) Licensee’s or Sublicensee’s use of
      the Technology or Intellectual Property Rights.

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    10.3  Licensor
      and Licensee each individually hereby represent and warrant that it has the
      full
      authority and power to enter into this Agreement.

     

    10.4  Licensor
      hereby represents and warrants that it is the lawful owner of the Technology
      and
      Intellectual Property Rights.

     

    10.5  Licensor
      and Licensee each individually hereby represent and warrant that it has the
      full
      right and authority to grant Licensee and Sublicensee, respectively, the rights
      set forth in this Agreement and it is and will not be a party to any other
      agreement or contractual arrangement which conflicts with this Agreement or
      the
      license and sublicense granted and contemplated in this Agreement; in
      particular, and without limiting the generality of the foregoing, the Technology
      and Intellectual Property Rights and the Licensee’s and Sublicensee’s use of the
      Intellectual Property Rights and Technology in accordance with this Agreement
      does not and will not infringe upon any other patent, copyright, trade secret,
      trademark, service mark, or trade name of any third-party, or contain any
      confidential or proprietary material misappropriated by the Licensor or
      Licensee. 

     

    10.6  Licensor
      and Licensee hereby represent and warrant that neither the Technology nor the
      Intellectual Property Rights does or will violate any applicable law, rule,
      or
      regulation, and that Licensor and Licensee possess all permits and licenses
      or
      related approvals required to comply with such laws, rules, and regulations.
      

     

    11.  CONFIDENTIALITY.
      All
      information furnished to the parties under this Agreement shall be treated
      as
      confidential and each party shall take reasonable precautions to preserve the
      confidentiality of this information until the termination of this Agreement.
      If
      this Agreement is terminated, each party shall return all documents and other
      materials containing, reflecting and referring to such information, except
      information, documents and other materials related to Derivative Works, and
      shall take reasonable precautions to preserve the confidentiality of this
      information. The parties’ obligations under this Agreement shall not apply to
      any information which: (i) was already in its possession prior to the disclosure
      thereof by the disclosing party, (ii) was then generally known to the public,
      (iii) became known to the public through no fault of the receiving party or
      any
      of its agents or representatives, or (iv) was disclosed to a party to this
      Agreement by a third party unaffiliated with any party to this Agreement who
      was
      not bound by an obligation of confidentiality.

     

    12.  MISCELLANEOUS.

     

    12.1  Amendments.
      The
      provisions of this Agreement may be amended, modified, waived or supplemented
      only by a written instrument duly executed by each party to this Agreement
      and
      making special reference to this Agreement. 

     

    12.2  Waivers.
      The
      failure or delay of any party at any time to require performance by another
      party of any provision of this Agreement, even if known, shall not affect the
      right of such party to require performance of that provision or to exercise
      any
      right, power or remedy under this Agreement. Any waiver by any party of any
      breach of any provision of this Agreement should not be construed as a waiver
      of
      any continuing or succeeding breach of such provision, a waiver of the provision
      itself, or a waiver of any right, power or remedy under this Agreement. No
      notice to or demand on any party in any circumstance shall, of itself, entitle
      such party to any other or further notice or demand in similar or other
      circumstances.

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    12.3  Severability.
      If any
      provision of this Agreement or any other agreement entered into pursuant hereto
      is or becomes illegal, invalid or unenforceable in any respect under the law
      of
      any jurisdiction, neither the legality, validity or enforceability of the
      remaining provisions of this Agreement nor the legality, validity or
      enforceability of such provision under the law of any other jurisdiction shall
      in any way be affected or impaired thereby. If any provision of this Agreement
      may be construed in two or more ways, one of which would render the provision
      invalid or otherwise voidable or unenforceable and another of which would render
      the provision valid and enforceable, such provision shall have the meaning
      which
      renders it valid and enforceable. In the event that any court finally holds
      that
      any of the terms and other provisions contained in this Agreement constitute
      an
      unreasonable restriction, then the parties agree that the provisions of this
      Agreement shall not be rendered void, but shall apply as to their time and
      territory or to such other extent as such court may judicially determine or
      indicate constitutes a reasonable restriction.

     

    12.4  Jurisdiction
      and Venue.
      Any
      legal proceeding or action arising out of or relating to this Agreement shall
      be
      brought in the appropriate state or Federal court located in Palm Beach County,
      Florida. Each party consents to the jurisdiction of such Florida court in any
      such civil action or legal proceeding and waives any objection to the laying
      of
      venue of any such civil action or legal proceeding in such court. Service of
      any
      court paper may be effected on such party by mail, as provided in this
      Agreement, or in such other manner as may be provided under applicable laws,
      rules of procedure or local rules.

     

    12.5  Governing
      Law.
      This
      Agreement and all transactions contemplated by this Agreement shall be governed
      by, and construed and enforced in accordance with, the laws of the State of
      Florida, without regard for principles of conflicts of law.

     

    12.6  Specific
      Performance as to Licensor.
      Licensee acknowledges that Licensor shall be irreparably damaged (and damages
      at
      law would be an inadequate remedy) if Sections 2, 6 or 8 of this Agreement
      are
      not specifically enforced. Therefore, in the event of a breach or threatened
      breach by Licensee of Sections 2, 6 or 8 of this Agreement, Licensor shall
      be
      entitled, in addition to all other rights and remedies, to injunctions
      restraining such breach, without being required to show any actual damage or
      to
      post any bond or other security, and to a decree for specific performance of
      the
      provisions of said Sections. 

     

    12.7  Counterparts;
      Faxed Signature Pages.
      This
      Agreement may be executed in one or more counterparts, each of which shall
      be
      deemed an original, but both of which taken together shall constitute one and
      the same instrument. Confirmation of execution by electronic transmission of
      a
      facsimile signature page shall be binding upon any party so
      confirming.

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    12.8  No
      Third Party Rights.
      Unless
      expressly stated in this Agreement to the contrary, nothing in this Agreement
      is
      intended to confer any rights or remedies under or by reason of this Agreement
      on any persons other than the parties to this Agreement and their respective
      successors, legal representatives and permitted assigns. Nothing in this
      Agreement is intended to relieve or discharge the obligation or liability of
      any
      third persons to any party to this Agreement, nor shall any provision give
      any
      third persons any right of subrogation or action over or against any party
      to
      this Agreement.

     

    12.9  No
      Construction Against Draftsman.
      The
      parties acknowledge that this is a negotiated agreement, and that in no event
      shall the terms of this Agreement be construed against any of the parties on
      the
      basis that such parties, or their respective counsel, drafted this
      Agreement.

     

    12.10  Survival.
      All
      covenants, agreements, representations and warranties made in this Agreement
      or
      otherwise made in writing by any party pursuant to this Agreement, including,
      without limitation Sections 2, 6 and 8 shall survive the termination of this
      Agreement.

     

    12.11  Assignment.
      Licensee and Sublicensee shall not assign this Agreement or any interest in
      this
      Agreement voluntarily, involuntarily, or by operation of law without Licensor’s
      prior written consent, which may be reasonably withheld in Licensor’s sole
      discretion. Licensor may assign its rights and obligations arising out of this
      Agreement without Licensee’s and Sublicensee’s prior consent; provided, however,
      Licensor must provide Licensee and Sublicensee with reasonable notice of such
      assignment in writing.

     

    12.12  Notices.
      All
      notices and other communications required or permitted under this Agreement
      shall be in writing and shall be given by hand delivery or by nationally
      recognized overnight delivery service (such as Federal Express, UPS, DHL or
      USPS
      Express Mail). All such notices and other communications shall be addressed
      to:

     

    
      	
              Licensor:

               

              Osmotex
                AS

              Contact:
                Svein Milford 

              Solheimsgaten
                16 A 

              N
                -
                5058 Bergen

              Norway

            

    

     

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

     

    
      	
              Licensee:

               

              Osmotex
                USA, Inc.

              c/o
                Osmotex AS

              Contact:
                Mr. Johnny Christiansen

              Solheimsgaten
                16A

              5080
                Bergen, Norway

            
	
               

              Sublicensee:

               

              IQ
                Micro Inc.

              Contact:
                Robert Rudman

              500
                Australian Ave., Ste. 700

              West
                Palm Beach, FL 33401

            

    

    

    Each
      such
      notice shall be deemed delivered (i) on the date delivered, if by messenger
      or
      courier service delivery; (ii) on the date of the confirmation of receipt,
      if by
      fax; and (iii) on the date of receipt or the date delivery is refused by the
      recipient, if by overnight delivery service.

     

    12.13  Entire
      Agreement.
      This
      Agreement and all exhibits and schedules attached to this Agreement, if any,
      represent the entire understanding and agreement among the parties with respect
      to the subject matter of this Agreement, and supersedes all other negotiations,
      understandings and representations (if any), whether oral or written, made
      by
      and between such parties.

     

    12.14  Limitation
      of Liability.
      Except
      for each party’s indemnity rights and obligations under Section 3 of this
      Agreement, and notwithstanding anything to the contrary contained herein, the
      parties to this Agreement each waive, to the fullest extent permitted by law,
      all claims against the other parties for indirect, incidental, special,
      exemplary, punitive or consequential damages otherwise recoverable under
      applicable laws arising in connection with this Agreement or the services to
      be
      provided under this Agreement, including, without limitation, damages resulting
      from loss of profits or earnings. EXCEPT IN CONNECTION WITH CLAIMS FOR PHYSICAL
      INJURIES, NO PARTY WILL BE LIABLE FOR (A) ANY SPECIAL, INCIDENTAL OR
      CONSEQUENTIAL DAMAGES, OR (B) COMMERCIAL LOSS OF ANY KIND, INCLUDING LOSS OF
      BUSINESS OR PROFITS, WHETHER BASED UPON BREACH OF WARRANTY, BREACH OF CONTRACT,
      NEGLIGENCE, STRICT TORT OR ANY OTHER LEGAL THEORY, WHETHER OR NOT ADVISED OF
      THE
      POSSIBILITY OF SUCH DAMAGES. 

     

    12.15  Binding
      Effect.
      All of
      the terms and provisions of this Agreement shall be binding upon, inure to
      the
      benefit of, and be enforceable by the parties and their respective legal
      representatives, successors and permitted assigns, whether so expressed or
      not.

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    12.16  Equitable
      Remedies.
      Each of
      the parties acknowledges that the parties will be irreparably damaged (and
      damages at law would be an inadequate remedy) if this Agreement is not
      specifically enforced. Therefore, in the event of a breach or threatened breach
      by any party of any provision of this Agreement, then the other parties shall
      be
      entitled, in addition to all other rights or remedies, (a) to an injunction
      restraining such breach, without being required to show any actual damage or
      to
      post an injunction or other bond, or (b) to a decree for specific performance
      of
      the provisions of this Agreement, or both.

     

    12.17  Expenses.
      Except
      as otherwise provided in this Agreement, each of the parties shall bear and
      pay
      all direct costs and expenses incurred by it or on its behalf in connection
      with
      the transactions contemplated by this Agreement, including, without limitation,
      the fees and expenses of its own financial or other consultants, investment
      bankers, accountants, and counsel.

     

    12.18  Further
      Assurances.
      The
      parties hereby agree from time to time to execute and deliver such further
      and
      other transfers, assignments and documents and do all matters and things that
      may be convenient or necessary to more effectively and completely carry out
      the
      intentions of this Agreement.

     

    12.19  Headings.
      The
      headings contained in this Agreement are for convenience of reference only,
      are
      not to be considered a part of the Agreement and shall not limit or otherwise
      affect in any way the meaning or interpretation of this Agreement.

     

    12.20  Pronouns
      and Terms.
      In this
      Agreement, the use of any gender shall be deemed to include all genders, and
      the
      use of the singular shall include the plural and vice versa, wherever it appears
      appropriate from the context. For all purposes of this Agreement, unless
      otherwise expressly stated to the contrary, the terms "hereby," "hereto,"
      "hereof," "hereunder" and "herein" shall refer to this entire Agreement; the
      term "person" shall include without limitation, any corporation, partnership,
      estate, trust, association, branch, bureau, subdivision, venture, associated
      groups, individual, government, institution, instrumentality and other entity,
      enterprise, association or endeavor of every nature and kind; and reference
      to
      the "business" of any person shall also be deemed to include, without
      limitation, the operations, financial condition, properties and prospects of
      such person.

     

    12.21  Export
      Control.
      Each
      party shall be responsible for ensuring that its actions with respect to the
      Technology and Intellectual Property Rights are in compliance with the import
      and export control laws of the United States and Norway (“Control
      Laws”).
      Each
      party will notify the other parties in writing if the Technology or Intellectual
      Property Rights is subject to any Control Laws, and will provide the appropriate
      parties with reasonable cooperation and information to assist the other in
      complying with any licensing or similar requirements that may be imposed under
      United States or Norway laws.

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

     

    12.22  Relationship
      of Parties.
      The
      parties agree that they are independent entities. Nothing in this Agreement
      shall be construed to create a partnership, joint venture, or agency
      relationship between or among the parties. Each party is responsible for the
      supervision, management and direction of its own employees. Each party is
      responsible for the payment of compensation to its employees and for any injury
      to them occurring in the course of their employment for which their employer
      is
      responsible and neither party shall be responsible for the supervision,
      management and direction of the employees of the other party.

     

    12.23  Reliance
      on Experts.
      For
      purposes of this Agreement, whenever one of the parties reasonably requires
      or
      retains the use of an expert in order to discharge a duty under this Agreement,
      such party's sole responsibility in connection with said duties shall be the
      reasonable reliance upon the advice of the experts, and no party shall be liable
      on account of any duty or obligation imposed under this Agreement in the event
      of a reliance upon professional advice.

     

    12.24  Enforcement
      Costs.
      If any
      civil action, arbitration or other legal proceeding is brought for the
      enforcement of this Agreement, or because of an alleged dispute, breach, default
      or misrepresentation in connection with any provision of this Agreement, the
      successful or prevailing party or parties shall be entitled to recover
      reasonable attorneys' fees, court costs, sales and use taxes and all expenses
      even if not taxable as court costs (including, without limitation, all such
      fees, taxes, costs and expenses incident to arbitration, appellate, bankruptcy
      and post-judgment proceedings), incurred in that proceeding, in addition to
      any
      other relief to which such party or parties may be entitled. Attorneys' fees
      shall include, without limitation, paralegal fees, investigative fees,
      administrative costs, sales and use taxes and all other charges billed by the
      attorney to the prevailing party (including any fees and costs associated with
      collecting such amounts).

     

    12.25  Arbitration.
      Notwithstanding anything to the contrary in this Agreement, all claims for
      monetary damages and disputes relating in any way to the performance,
      interpretation, validity, or breach of this Agreement shall be referred to
      final
      and binding arbitration, before a single arbitrator, under the commercial
      arbitration rules of the American Arbitration Association in Broward County,
      Florida. The parties shall select the arbitrator and if the parties are unable
      to reach agreement on selection of the arbitrator within ten days after the
      notice of arbitration is served, then the American Arbitration Association
      will
      select the arbitrator. All documents, materials, and information in the
      possession of a party to this Agreement and in any way relevant to the claims
      or
      disputes shall be made available to the other parties for review and copying
      not
      later than sixty days after the notice of arbitration is served. To the extent
      that a party would be required to make confidential information available to
      any
      other, an agreement or an order shall be entered in the proceeding protecting
      the confidentiality of and limiting access to such information before a party
      is
      required to produce such information. Information produced by a party shall
      be
      used exclusively in the arbitration or litigation that may arise, and shall
      not
      otherwise be disclosed. In no event shall a party be entitled to punitive
      damages in any arbitration or judicial proceeding and all parties hereby waive
      their rights to any punitive damages. In the event an arbitration panel or
      a
      court concludes that the punitive damages waiver contained in the previous
      sentence is unenforceable, then the parties agree that the court with subject
      matter jurisdiction over the confirmation of the award shall have sole and
      exclusive jurisdiction to determine issues of entitlement and amount of punitive
      damages. The arbitrator shall not have subject matter jurisdiction to decide
      any
      issues relating to the statute of limitations or to any request for injunctive
      relief, and the parties hereby stipulate to stay the arbitration proceeding
      (without the need of a bond) until any such issues in dispute are resolved.
      Judgment upon the award rendered by the arbitrator shall be final, binding
      and
      conclusive upon the parties and their respective administrators, personal
      representatives, legal representatives, heirs, successors and permitted assigns,
      and may be entered in any court of competent jurisdiction.

     

    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

    

     

     

    

    [REMAINDER
      OF PAGE PURPOSEFULLY LEFT BLANK]

     

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the duly authorized representatives of each party hereto have
      executed this Amended and Restated Technology License Agreement on the date
      first above written.

     

    
      	 	 	 
	 	OSMOTEX
              AS
	 
 	 
 	 
 
	 	By:  	 
	 	
              
Name:
	 	Title:

    

     

     

    
      	 	 	 
	 	OSMOTEX
              USA, INC.
	 
 	 
 	 
 
	 	By:  	 
	 	
              
Name:
	 	Title:

    

     

     

    
      	 	 	 
	 	IQ
              MICRO
              INC.
	 
 	 
 	 
 
	 	By:  	/s/ R.
              Rudman
	 	
              
Name:
              R. Rudman
	 	Title:
              Director & CFO

    

     

     

    
      
        
        

      

      
        16

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF, the duly authorized representatives of each party hereto have
      executed this Amended and Restated Technology License Agreement on the date
      first above written.

     

    
      	 	 	 
	 	OSMOTEX
              AS
	 
 	 
 	 
 
	 	By:  	/s/ Johnny
              Christiansen
	 	
              
Name:
Johnny
              Christiansen
	 	Title: Chairman
              of Board

    

     

    
       

    

    
      	 	 	 
	 	OSMOTEX
              USA, INC.
	 
 	 
 	 
 
	 	By:  	/s/ Johnny
              Christiansen
	 	
              
Name:
Johnny
              Christiansen
	 	Title: CEO/Chairman

    

     

     

    
      	 	 	 
	 	IQ
              MICRO
              INC.
	 
 	 
 	 
 
	 	By:  	/s/ Johnny
              Christiansen
	 	
              
Name:
Johnny
              Christiansen
	 	Title: CEO

    

     

     

    
      
        
        

      

      
        17

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

     

    DESCRIPTION
      OF TECHNOLOGY

     

    Patents
      for the patent application titled “Method
      Of Fluid Transport”
      in:

     

    l Australia
      (AU737492)

     

    l Brazil
      (PI9810358.0)

     

    l Canada
      (CA2295710) 

     

    l Finland
      (FI0993328)

     

    l France
      (FR0993328)

     

    l Germany
      (DE0993328)

     

    l Great
      Britain (GB0993328)

     

    l Italy
      (IT0993328)

     

    l Norway
      (NO308095)

     

    l United
      States (US6320160). 

     

    The
      patent application priority date for the foregoing patents was June 30,
      1997.EXHIBIT
      10.25
 

    AMENDMENT
      TO

    CAPITAL
      CONTRIBUTION AGREEMENT

    

    THIS
      AMENDMENT TO CAPITAL CONTRIBUTION AGREEMENT (the
      “Agreement”)
      is
      made and entered into as of January 12, 2006 by
      and
      among IQ
      MICRO INC. (formerly
      IQ Medical Corp.), a Colorado corporation (“IQMC”),
      and
OSMOTEX
      USA, INC., a
      Florida
      corporation (“Osmotex”)
      (individually, the “Party”
and
      collectively, the “Parties”).

    

    RECITALS

    

    WHEREAS,
      the
      Parties entered into that certain Capital Contribution Agreement, on June 9,
      2005, (the “Original
      Agreement");
      

    

    WHEREAS,
      the
      Parties and Osmotex AS entered into the
      Amended and Restated Technology License Agreement (the “License
      Agreement”)
      on
      January 12, 2006, attached hereto as Exhibit
      A;
      and

    

    WHEREAS,
      the
      Parties desire to amend the Original Agreement to reflect IQMC’s payment of a
      license fee to Osmotex; and

    

    WHEREAS,
      Section
      6.3 of the Original Agreement provides that the Original Agreement may only
      be
      amended by a subsequent writing signed by all Parties; and

    

    WHEREAS,
      the
      Parties wish to document their agreement regarding these matters in this
      Agreement.

    

     NOW,
      THEREFORE,
      in
      consideration of the mutual terms, conditions and other agreements set forth
      herein, and for other valuable consideration, the receipt and adequacy of which
      are hereby conclusively acknowledged, the Parties hereto, intending to be
      legally bound, hereby agree as follows:

    

    1. Recitals.
      The
      foregoing recitals are true and correct. Each of the foregoing recitals to
      this
      Agreement are hereby incorporated into and made a part of this
      Agreement.

    

    2. Definitions.
      Unless
      indicated otherwise, each capitalized term used in this Agreement shall have
      the
      same meaning as set forth in the Original Agreement.

    

    3. Amendment
      of Article 1 of the Agreement.
      

    

    3.1 The
      heading of Article I of the Agreement is hereby deleted in its entirety and
      replaced with the following:

    

    “CAPITAL
      CONTRIBUTION; ISSUANCE OF SHARES; LICENSE FEE”

    
 

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

     

    3.2 Section
      1.1 of Article I is hereby deleted in its entirety and replaced with the
      following:

    

    “(a) CAPITAL
      CONTRIBUTION AND ISSUANCE OF SHARES.
      Upon the terms and subject to the conditions set forth in this Agreement and
      in
      connection with the License Agreement, Osmotex contributed the Technology and
      Intellectual Property Rights (as defined in the License Agreement) (the “Capital
      Contribution”) to IQMC as a contribution to the capital of IQMC. IQMC accepted
      this Capital Contribution. In exchange for this Capital Contribution, IQMC
      issued 42,670,000 shares of its $0.0001 par value per share common stock (the
      “Shares”) to Osmotex.

    

    (b) LICENSE
      FEE.
      IQMC made payment of a license fee in the amount of $300,000 (the “License Fee”)
      of which Osmotex hereby acknowledges receipt and further acknowledges that
      IQMC
      did pay the License Fee in full.”

    

    4. Amendment
      to Section 2.3(c) of Article 2 of the Agreement.
      Section
      2.3(c) of Article 2 is hereby deleted in its entirety and replaced with the
      following:

    

    “Schedule
      2.3(c)
      contains a true and complete list of all of the shareholders of record on
      December 29, 2005 of IQMC Capital Stock along with the amounts owned by each
      such party.”

     

    5. Amendment
      to Section 2.4 of Article 2 of the Agreement.
      Section
      2.4 of Article 2 is hereby deleted in its entirety and replaced with the
      following:

    

    “INVESTMENTS;
      SUBSIDIARIES.
      Except as set forth in Schedule
      2.4,
      IQMC currently does not have and has never owned any subsidiary corporation,
      partnership or other business entity and has never made any investments in
      any
      other corporation, partnership or other business entities.”

    

    6. Amendment
      to Section 2.10 of Article 2 of the Agreement.
      Section
      2.10 of Article 2 is hereby deleted in its entirety and replaced with the
      following:

      

    “REAL
      PROPERTY.
      Except as set forth in Schedule
      2.10,
      IQMC does not currently own or lease any real property and has never owned
      or
      leased any real property.”

      

    7.Amendment
      to Section 2.14 of Article 2 of the Agreement.
      Section
      2.14 of Article 2 is hereby deleted in its entirety and replaced with the
      following:

      

    “MATERIAL
      CONTRACTS.
      Except as set forth in Schedule
      2.14,
      IQMC is not a party to any material contract or agreement (oral or
      written).”

     

    8. Amendment
      of Section 6.6 of Article 6 of the Agreement.
      Section
      6.6 of Article 6 of the Agreement is hereby deleted in its entirety and replaced
      with the following:

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    
 

    “NOTICES.
      All notices, requests, consents and other communications required or permitted
      under this Agreement shall be in writing and shall be (as elected by the Person
      giving such notice) hand delivered by messenger or courier service or mailed
      by
      registered or certified mail (postage prepaid), return receipt requested,
      addressed to:

      

    
      
        	
                IQMC:
                  

              	
                IQ
                  Micro Inc.

                Attention:
                  Robert V. Rudman

                500
                  Australian Avenue, Suite 700

                West
                  Palm Beach, FL 33401

                561/514-0118

              
	
                 

                OSMOTEX:
                  

              	
                 

                Osmotex
                  USA, Inc.

                c/o
                  Osmotex AS

                Attention:
                  Svein Milford

                Solheimsgaten
                  16A

                5080
                  Bergen, Norway

                 

              

      

     

    or
      to such other address as any Party may designate by notice complying with the
      terms of this Section. Each such notice shall be deemed delivered (a) on
      the date delivered, if by messenger or courier service; and (b) either upon
      the date of receipt or refusal of delivery, if mailed.

     

    [REMAINDER
      OF PAGE INTENTIONALLY LEFT BLANK]

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF,
      the
      Parties hereto have executed this Amendment to Capital Contribution Agreement
      as
      of the date first above written.

    

    
      	 	 	 
	 	IQ
              MICRO
              INC.
	 
 	 
 	 
 
	 	By:  	/s/
              Robert V. Rudman
	 	
              
Name:
 Robert
              V. Rudman
	 	
              Its:
                  Chief
                Financial Officer, 

              Secretary and
                Treasurer

            

    

     

     

    
 

    
      
        	 	 	 
	 	OSMOTEX
                USA, INC.
	 
 	 
 	 
 
	 	By:  	/s/
                Johnny Christiansen
	 	
                
Name:
                Johnny Christiansen
	 	Its:  

      

    
 

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    

    

    EXHIBIT
      A

    

    AMENDED
      AND RESTATED TECHNOLOGY LICENSE AGREEMENT

    

     

     

     

     

    
 

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    
 

    
      	
              SCHEDULE
                2.3(c)

               

              CAPITAL
                STOCK

            
	
               

               

              NAME
                AND ADDRESS

            	
               

              TOTAL
                SHARES

            	 	
               

               

              NAME
                AND ADDRESS

            	
               

              TOTAL
                SHARES

            
	 	 	 	 	 
	
              Albany
                Consulting, Inc.

              c/o
                OCRA, Companies House

              Tower
                Street

              Ramsey

              Isle
                of Man

            	
              1,500

            	 	
              ALEXIS
                CAPITAL, INC.

              74900
                Highway 111, #123

              Indian
                Wells, CA 92210

            	
              1,000

            
	 	
               

            	 	 	 
	
              Avalon
                Marketing Ltd.

              500
                Australian Avenue So., #619

              West
                Palm Beach, FL 33401

            	
              1,750,000

            	 	
              Debora
                J. Borer

              7400
                E. Columbia Place

              Denver,
                CO 80231

            	
              100

            
	 	 	 	 	 
	
              John
                Burchette

            	
              250

            	 	
              Cede
                & Co.

              P.O.
                Box 20, Bowling Green Station

              New
                York, NY 10274

            	
              1,198,157

            
	 	 	 	 	 
	
              Abigail
                Doolittle

              231
                West 96th
                Street, #6C

              New
                York, NY 10025

            	
              125

            	 	
              Equity
                Investors, Inc.

              4530
                North 40th
                Street

              Phoenix,
                AZ 85018

            	
              100

            
	 	 	 	 	 
	
              Mary
                C. Fernandez

              P.O.
                Box 14411

              Albuquerque,
                NM 87111

            	
              100

            	 	
              Gregory
                Frost

              Tanner
                Propp & Farber

              99
                Park Avenue

              New
                York, NY 10016

            	
              500

            
	 	 	 	 	 
	
              Golden
                Capital Securities Ltd. 

              in
                Trust/Oxbridge Capital Limited

              Suite
                168

              1177
                West Hastings Street

              Vancouver,
                B.C.

              Canada
                V6E 2K3

            	
              1,250,000

            	 	
              Hossian
                Hafizi & Nahid 

              Hafizi,
                JTTEN

              10409
                NE 32nd
                Pl. Num. 8104

              Bellevue,
                WA 98004-1981

            	
              100

            
	 	 	 	 	 
	
              Impact
                Trading, Inc.

              1451
                W. Cypress Creek Rd., #204

              Ft.
                Lauderdale, FL 33309

            	
              1,250,000

            	 	
              Philip
                Johnston

              26
                King Street

              St.
                Pacome

              Quebec

              Canada
                GOL 3X0

            	
              1,750,000

            
	 	 	 	 	 
	
              Paul
                Kempin

              29752
                Baden Place

              Malibu,
                CA 90265

            	
              1,000

            	 	
              Lamlash
                Limited

              c/o
                Montague Sec Int’l Safety Square

              Bay
                Street & Bank Lane

              PO
                Box N-8303

              Nassau
                BAHAMAS

            	
              100

            
	 	 	 	 	 

    

     

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    
      	
              SCHEDULE
                2.3(c)

               

              CAPITAL
                STOCK

              (continued)

            
	
               

               

              NAME
                AND ADDRESS

            	
               

              TOTAL
                SHARES

            	 	
               

               

              NAME
                AND ADDRESS

            	
               

              TOTAL
                SHARES

            
	 	 	 	 	 
	
              Millenium
                Capital Corporation

              500
                Australian Ave. So., #619

              West
                Palm Beach, FL 33401

            	
              250,000

            	 	
              Millport
                Limited

              Suite
                No. 2, Seaton Place

              St.
                Heller, Jersey

              Channel
                Islands JE2 3QL

            	
              263

            
	 	 	 	 	 
	
              Montague
                Securities Int’l

              Saffrey
                Square Ste. 103A

              Bay
                Street Bank, LA Box N 8303

              Nassau
                N.P. BAHAMAS

            	
              3,815

            	 	
              Osmotex,
                USA, Inc.

              c/o
                Gunster Yoakley & Stewart, P.A.

              Broward
                Financial Center

              500
                East Broward Blvd., #1400

              Fort
                Lauderdale, FL 33394-3076

            	
              42,670,000

            
	 	 	 	 	 
	
              Donna
                Ann Perrotta

              83
                Throckmorton Lane

              Old
                Bridge, NJ 08857

            	
              750

            	 	
              Jonathan
                Pollon

              461
                Promontory Drive

              West
                Newport Beach, CA 92660

            	
              500

            
	 	 	 	 	 
	
              David
                Rapaport

              11666
                Montana Avenue

              Los
                Angeles, CA 90049

            	
              1,000

            	 	
              Richard
                D. Salpeter

              3
                Grove Isle Drive, Apt. 1705

              Coconut
                Grove, FL 33133

            	
              427

            
	 	 	 	 	 
	
              Patrick
                J. Soltis

              125
                Armistead Ct.

              Duluth,
                GA 30097

            	
              10,438

            	 	
              Swiss
                Corp. International

              125
                Armistead Ct.

              Duluth,
                GA 30097

            	
              1,925

            
	 	 	 	 	 
	
              Mark
                Taggatz

              350
                Kachina Cr.

              Las
                Vegas, NV 89123

            	
              55,000

            	 	
              Keith
                Taylor-Sharpe

              2169
                Inglehart Avenue

              St.
                Paul, MN 55104

            	
              250

            
	 	 	 	 	 
	
              Teekachand
                Tiwari

              924
                N. Eighteenth Cr. #10

              Hollywood,
                FL 33020

            	
              2,000

            	 	
              Derek
                Vanderryst

              1023
                West Lake

              Ft.
                Collins, CO 80523

            	
              100

            

    

     

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    

    SCHEDULE
      2.4

    

    INVESTMENTS;
      SUBSIDIARIES

    

    On
      July
      21, 2005, we formed IQ Micro (USA) Inc., a Florida corporation and our
      wholly-owned subsidiary. 

    

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    SCHEDULE
      2.10

    

    REAL
      PROPERTY

    

    Our
      executive office is located at 500 Australian Avenue, Suite 700, West Palm
      Beach, Florida, 33401. We have verbally agreed to a month-to-month lease for
      this single executive office in a shared office suite at a current lease rate
      of
      $2,500 per month.

    

    

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

    SCHEDULE
      2.14

    

    MATERIAL
      CONTRACTS

    

    
      	
              1.  

               

            	 	
              Plan
                of Merger Enclave Products, Ltd. by and between Enclave Products,
                Ltd., a
                Colorado corporation, and Enclave Products, Ltd., a Colorado corporation,
                dated March 29, 2004. 

               

            
	
              2.  

               

            	 	
              Financing
                and Listing Agreement by and among IQ Medical Corp., Osmotex USA,
                Inc. and
                D.P. Martin & Associates, Inc., entered into on June 9,
                2005.

               

            
	
              3.  

               

            	 	
              Amendment
                to Financing and Listing Agreement by and among IQ Micro Inc., Osmotex
                USA, Inc. and D.P. Martin & Associates, Inc., entered into on December
                29, 2005.

               

            
	
              4.  

               

            	 	
              Capital
                Contribution Agreement by and among IQ Medical Corp. and Osmotex
                USA,
                Inc., entered into on June 9, 2005.

               

            
	
              5.  

               

            	 	
              Amended
                and Restated Technology License Agreement by and among IQ Micro Inc.,
                Osmotex AS and Osmotex USA, Inc. entered into on January 12,
                2006

               

            
	
              6.  

               

            	 	
              Securities
                Purchase Agreement by and among IQ Medical Corp. and Cornell Capital
                Partners, LP, dated as of August 12, 2005.

               

            
	
              7.  

               

            	 	
              Secured
                Convertible Debenture issued by IQ Medical Corp. to Cornell Capital
                Partners, LP, dated August 12, 2005.

               

            
	
              8.  

               

            	 	
              Warrant
                issued by IQ Medical Corp. to Cornell Capital Partners, LP, dated
                August
                12, 2005.

               

            
	
              9.  

               

            	 	
              Escrow
                Agreement by and among IQ Medical Corp. and David Gonzalez, Esq.,
                made and
                entered into as of August 12, 2005.

               

            
	
              10.  

               

            	 	
              Security
                Agreement by and between IQ Medical Corp. and Cornell Capital Partners,
                LP, entered into and made effective on August 12, 2005.

               

            
	
              11.  

               

            	 	
              Investor
                Registration Rights Agreement by and among IQ Medical Corp. and Cornell
                Capital Partners, LP, dated as of August 12, 2005.

               

            
	
              12.  

               

            	 	
              Securities
                Purchase Agreement by and among IQ Micro Inc. and Cornell Capital
                Partners, LP, dated as of November 30, 2005.

               

            
	
              13.  

               

            	 	
              Warrant
                issued by IQ Micro Inc. to Cornell Capital Partners, LP, dated November
                30, 2005.

               

            
	
              14.  

               

            	 	
              Secured
                Convertible Debenture issued by IQ Micro Inc. to Cornell Capital
                Partners,
                LP, dated November 30, 2005.

               

            
	
              15.  

               

            	 	
              Amended
                and Restated Investor Registration Rights Agreement by and among
                IQ Micro
                Inc. and Cornell Capital Partners, LP, dated as of November 30,
                2005.

               

            

    

     

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    
      	
              SCHEDULE
                2.14

               

              MATERIAL
                CONTRACTS 

              (continued)

               

            
	
              16.  

               

            	 	
              Amended
                and Restated Security Agreement by and between IQ Micro Inc. and
                Cornell
                Capital Partners, LP, entered into and made effective on November
                30,
                2005.

               

            
	
              17.  

               

            	 	
              Escrow
                Agreement by and among IQ Micro Inc. and David Gonzalez, Esq., made
                and
                entered into as of November 30, 2005.

               

            
	
              18.  

               

            	 	
              Management
                Agreement between I.Q. Medical Corp. and Robert Rudman, effective
                as of
                May 1, 2005.

               

            
	
              19.  

               

            	 	
              Management
                Agreement between I.Q. Micro Inc. and Jochri Consult AS, effective
                as of
                October 1, 2005.

               

            
	
              20.  

               

            	 	
              Consulting
                Agreement between Hawk Associates, Inc. and IQ Micro, made as of
                August 1,
                2005 for investor relations and financial media relations
                services.

               

            
	
              21.  

               

            	 	
              Consulting
                Agreement between Hawk Associates, Inc. and IQ Micro, made as of
                September
                1, 2005 for investor relations and financial media relations
                services.

               

            

    

    

    * Anticipated
      to be executed on the same date as this Agreement.

     

     

    
      
        
        

      

        11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}]]